Artivion (AORT) Stock Price, News & Analysis

Company Overview

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Key Stats

• Today's Range: $28.41 to $28.97
• 50-Day Range: $22.13 to $29.79
• 52-Week Range: $21.97 to $32.33
• Volume: 369,637 shs
• Average Volume: 330,895 shs
• Market Capitalization: $1.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.40
• Consensus Rating: Buy

Artivion Stock Analysis - MarketRank™

Artivion scored higher than 29% of companies evaluated by MarketBeat, and ranked 817th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Buy

Consensus Rating

Artivion has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Artivion has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 35.14%

Earnings Growth

Earnings for Artivion are expected to grow by 35.14% in the coming year, from $0.37 to $0.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Artivion is -1,439.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Artivion is -1,439.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Artivion has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.90% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Artivion has recently increased by 20.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Artivion does not currently pay a dividend.

Dividend Growth

Artivion does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.90% of the float of Artivion has been sold short.

Short Interest Ratio / Days to Cover

Artivion has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Artivion has recently increased by 20.22%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.70

News Sentiment

Artivion has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Artivion this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added Artivion to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,716,731.00 in company stock.

Percentage Held by Insiders

Only 7.60% of the stock of Artivion is held by insiders.

Percentage Held by Institutions

86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AORT Stock Analysis - Frequently Asked Questions

How have AORT shares performed this year?

Artivion's stock was trading at $28.59 on January 1st, 2025. Since then, AORT stock has increased by 0.7% and is now trading at $28.79.
View the best growth stocks for 2025 here.

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) released its earnings results on Monday, May, 5th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.12 by $0.06. The company earned $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. Artivion had a negative net margin of 0.22% and a positive trailing twelve-month return on equity of 5.15%.
Read the conference call transcript.

Who are Artivion's major shareholders?

Top institutional investors of Artivion include Vanguard Group Inc. (6.52%), Wellington Management Group LLP (4.05%), GW&K Investment Management LLC (2.52%) and Next Century Growth Investors LLC (2.40%). Insiders that own company stock include James P Mackin, David Ashley Lee, John E Davis, Jean F Holloway, Amy Horton, Marshall S Stanton, Lance A Berry, Rochelle L Maney, Dennis B Maier, Matthew A Getz, Andrew M Green and Anthony B Semedo.
View institutional ownership trends.

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Artivion own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 6/03/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:AORT
• CIK: 784199
• Web: www.cryolife.com
• Phone: (770) 419-3355
• Fax: 770-426-0031
• Employees: 1,300
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.40
• High Stock Price Target: $33.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +10.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 76.99
• P/E Growth: N/A
• Net Income: -$30.69 million
• Net Margins: -0.22%
• Pretax Margin: 2.21%
• Return on Equity: 5.15%
• Return on Assets: 1.91%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 1.88
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $390.08 million
• Price / Sales: 3.12
• Cash Flow: $0.77 per share
• Price / Cash Flow: 36.78
• Book Value: $6.87 per share
• Price / Book: 4.15

Miscellaneous

• Outstanding Shares: 42,703,000
• Free Float: 38,524,000
• Market Cap: $1.22 billion
• Optionable: Optionable
• Beta: 1.54